• Inventage Lab applied for Australian Phase 1 trial approval for IVL3021, its long-acting semaglutide injection, on Oct. 28, 2026.
• The obesity trial will compare IVL3021 with Wegovy in 40 healthy overweight adults over approximately 12 months from approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventage Lab Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261028900317), on October 28, 2026, and is solely responsible for the information contained therein.